The Ken is launching a Southeast Asia edition soon. Join the waitlist to get early access

Self goal

HCG is fighting the govt to keep cancer drugs costly…

So the poor don’t end up subsidising the rich instead

24/04/19

Suraksha P

On 27 February, India's apex pharmaceutical pricing authority capped the trade margin of 42 cancer drugs at 30%

All told, some 517 brands of cancer medication have now seen their prices drop as a result of price control. Some by up to 87%

HCG, India's largest private chain of cancer hospitals, challenged the order in the Karnataka High Court

While HCG has faced backlash for this, it argues that price control will only hurt the vulnerable patients it was meant to help

4135527711_1f3d4d7a98_o-1920x1080.jpg

Having spent over three decades practising Oncology in the US and India, Dr BS Ajaikumar is hardly one for the limelight. Just last month, however, Dr Ajaikumar, chairman and CEO of Healthcare Global Enterprises (HCG), India’s largest private chain of cancer hospitals, found himself the villain of the piece on social media.

Read the full story. Create a free account.

Also read our exhaustive coverage about Impact of Regulation, Health and Hospital Chains and Pharma Drugs

Or subscribe. Why? Let us explain.

Already Registered?

Related stories

More stories in /Healthcare & /Reportage

See all in Business & Reportage

Want to read this story for free right now? Just

Read the full story instantly.
Just enter your email address.

Also read our exhaustive coverage about Impact of Regulation, Health and Hospital Chains and Pharma Drugs

Or subscribe. Why? Let us explain.

Or

By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.

What you get

Access all free stories

244+ archived free stories, and all upcoming ones too.

Paid story summaries

Read an exclusive 200 word summary for all our paid stories.

Daily Newsletters

Our world-renowned emails, in your inbox, every day.

Or get full access to all our stories

About subscriptions

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

915+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.